These results highlight the risk of VEGF inhibitors usage in cancer therapy by providing evidence that inhibition of VEGF signaling impairs hypoxia-induced neurogenesis and angiogenesis as well as causing cognitive impairment. Here, VEGFA is linked to Cognitive impairment.